OTC clemastine data for common cold can be generalized to children -- FDA advisory cmte..
This article was originally published in The Tan Sheet
Executive Summary
OTC CLEMASTINE DATA CAN BE GENERALIZED TO PEDIATRIC POPULATIONS for treatment of the common cold, FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees agreed at a Nov. 16 joint meeting in Rockville, MD. The committees voted 12-3 that the common cold is sufficiently similar in the adult and pediatric populations to allow the results of Sandoz' two randomized, double-blind, placebo-controlled trials to be extrapolated to children six to 12.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning